-- 根據週一提交給台灣交易所的文件顯示，Caliway Biopharmaceuticals（股票代號：TPE:6919）已完成向美國FDA提交的減脂藥物第三期臨床試驗的IND申請。 週二午後交易中，該公司股價上漲約5%。 研究將評估名為CBL-514的藥物在減少腹部皮下脂肪的療效。 這項隨機、雙盲、安慰劑對照試驗將在美國、加拿大和澳洲招募約320名受試者。 該公司在文件中表示，該申請已於週一提交，目前正在審核中。
Related Articles
Australia
Brazilian Rare Earths Targets Brazil Critical Minerals Province Scoping Study, Mineral Resource Estimate for Mid-2026; Shares Up 4%
Brazilian Rare Earths (ASX:BRE) said that the mineral resource estimate and scoping study for the Rocha da Rocha critical minerals province are both targeted for mid-2026, according to a Monday Australian bourse filing.Sensor-based ore sorting testing validated a simple, dry beneficiation pathway for the Monte Alto project, while a metallurgical optimization program validated low-temperature acid-cure processing at 150 degrees celsius, with a 15 kilograms blended composite scale-up test confirming high extraction performance and strong scalability, the filing said.The company expects to submit an economic development plan for the project to Brazil's National Mining Agency in the June quarter.Brazilian Rare Earths' shares rose nearly 4% in recent trading on Monday.
$ASX:BRE
Asia
CITIC Securities' Profit Surges 55% in Q1
CITIC Securities (HKG:6030, SHA:600030) posted net profit attributable to owners of 10.2 billion yuan for the first quarter of 2026, up 55% from 6.61 billion yuan a year earlier, according to an April 24 Hong Kong bourse filing.Hong Kong-listed shares of the firm were up nearly 2% in Monday morning trade.Earnings per share came in at 0.67 yuan, compared with 0.43 yuan in the prior-year period.Operating revenue rose 41% to 23.2 billion yuan from 16.4 billion yuan.
$HKG:6030$SHA:600030
Asia
NHU's Q1 Profit Rises 15%, Revenue Climbs 3%
Zhejiang NHU's (SHE:002001) net profit attributable to shareholders in the first quarter rose 15% to 6.76 billion yuan from 5.87 billion yuan a year earlier, according to a Saturday filing on the Shenzhen bourse.Earnings per share climbed 16% year on year to 2.21 yuan from 1.91 yuan.Operating revenue increased 3% to 22.3 billion yuan from 21.6 billion yuan in the prior year.
$SHE:002001